Based on the decline in alcohol demand attributed to GLP-1 weight loss drugs, I believe Brown-Forman is facing significant sales challenges. This coul...
Read
More
Based on the decline in alcohol demand attributed to GLP-1 weight loss drugs, I believe Brown-Forman is facing significant sales challenges. This could result in further downward pressure on their stock price over the medium term.